Lineage's OpRegen RPE cell therapy program was licensed by Roche and Genentech.
2 reports, 2 independent
Updated Aug 9
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Lineage's OpRegen RPE cell therapy program was licensed by Roche and Genentech.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA cleared material for OpRegen clinical trials; Roche/Genentech optimizing surgical delivery.1 source
Lineage licensed its OpRegen RPE cell therapy program to both Roche and Genentech.1 source
Keep exploring
The entities involved
-
Lineage
temperature-controlled warehousing and logistics company
-
Hoffmann-La Roche
Swiss healthcare company
Related events
Coverage
Newest first; wire copies grouped- yahoo.com
- Business WireLineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Positive RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials